Last Updated: May 19, 2016
- A Genetic Lung Cancer Susceptibility Test may have a Positive Effect on Smoking Cessation.
Kammin Tammy et al. Journal of genetic counseling 2015 Jun 24(3) 522-31 - MTHFR C677T and A1298C polymorphisms and risk of lung cancer: a comprehensive evaluation.
Yang Y, et al. Genetics and molecular research : GMR 2016 0 (2) - Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population.
Xiao H L, et al. Genetics and molecular research : GMR 2016 0 (2) - Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients.
Mir Rashid, et al. South Asian journal of cancer 0 0 (1) 33-6 - Combining Telomerase Reverse Transcriptase Genetic Variant rs2736100 with Epidemiologic Factors in the Prediction of Lung Cancer Susceptibility.
Wang Xu, et al. Journal of Cancer 2016 0 (7) 846-53 - Characteristics of smoking lung cancer patients with emphysematous bullae.
Iwama Eiji, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 5 - Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Wang Tian-Lu, et al. Clinical laboratory 2016 0 (3) 301-10 - Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
Medairos Robert A, et al. The Journal of thoracic and cardiovascular surgery 2016 4 - Clinical Implications of Genomic Discoveries in Lung Cancer
C Swanton et al, NEJM, May 12, 2016 - Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh James H et al. The oncologist 2016 May - The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
Hung Hsiu-Ying, et al. Integrative cancer therapies 2016 5 - Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.
Valmori Danila, et al. Oncoimmunology 2016 4 (4) e947175 - Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Bonanno Laura, et al. Lung cancer (Amsterdam, Netherlands) 2016 6 52-5 - EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit Perrine, et al. Lung cancer (Amsterdam, Netherlands) 2016 6 74-7 - Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Zhou Lin, et al. Lung cancer (Amsterdam, Netherlands) 2016 6 93-100 - EGFR mutation status on brain metastases from non-small cell lung cancer.
Hsu Fred, et al. Lung cancer (Amsterdam, Netherlands) 2016 6 101-7 - Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population.
Liu Qing-Feng, et al. Lung 2016 4 - Validation of Rapid Plasma Genotyping for Detecting EGFR and KRAS Mutations in Advanced Lung Cancer,
by Matthew Stenger, ASCO Post, April 29, 2016 - Review of the Gene-Environment Interaction Literature in Cancer: What Do We Know?
Simonds Naoko I et al. Genetic epidemiology 2016 Apr - Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim Sun Min, et al. Oncotarget 2016 4 - Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model.
Marcus Michael W, et al. International journal of oncology 2016 4 - Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China.
Chen Yun, et al. Molecular and clinical oncology 2016 5 (5) 749-755 - Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.
Inomata Minehiko, et al. Molecular and clinical oncology 2016 5 (5) 774-778 - Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer.
Miyazaki Kunihiko, et al. Molecular and clinical oncology 2016 5 (5) 873-877 - [Clinical Analysis of Icotinib on Beneficiary of ?Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Jiang Xiaowen, et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2016 4 (4) 200-6 - Elevated integrin ?6?4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.
Stewart Rachel L, et al. Human pathology 2016 4 - The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi Veronika, et al. Pathology oncology research : POR 2016 4 - Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.
Wen Miaomiao, et al. OncoTargets and therapy 2016 0 1989-95 - Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects.
Yu Xiongjie, et al. OncoTargets and therapy 2016 0 2049-56 - Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho Kyoung Min, et al. The Korean journal of internal medicine 2016 4
- Human (3738)
- Pathogen (0)
- Human (56)
- Pathogen (0)
.png)
No hay comentarios:
Publicar un comentario